Why BGPT?
logo

Paper Review β€” verify claims with raw data

Extract figures, tables, methods, and underlying data to audit results.

Press Enter ↡ to review



    Explore by Goal




     Quick Explanation


    What the paper is doing (and what it is not): This article is a systematic review claiming that sulforaphane (SFN) from broccoli modulates epigenetic mechanisms (HDAC/DNMT regulation, histone acetylation, DNA methylation, and miRNA) to suppress cancer cell proliferation and tumor formation in preclinical models.
    Key skepticism point: the paper summarizes many heterogeneous preclinical studies and repeatedly uses mechanistic language (HDAC/DNMT inhibition β†’ acetylation/methylation changes β†’ tumor suppression) without providing a quantitative synthesis (e.g., effect sizes, heterogeneity metrics), and it includes broad disease claims beyond direct cancer endpoints.



     Long Explanation


    Paper Review (Systematic Review): β€œSulforaphane from broccoli, an epigenetic modulator in cancer cells”
    DOI: 10.1007/s12672-025-03580-2 β€’ Received 31 Dec 2024 / Accepted 3 Sep 2025 (as provided in the paper text)
    Single-sentence summary of the paper’s claim
    The review argues that sulforaphane (SFN) acts as an epigenetic modulator in cancer by downregulating HDACs and DNMTs, increasing histone acetylation, promoting DNA hypomethylation, and altering miRNA profilesβ€”leading to apoptosis, cell-cycle arrest, and reduced tumor progression in preclinical models.
    1) Evidence synthesis structure (PRISMA-stated workflow)
    The authors state they conducted a systematic review following PRISMA and searched PubMed and Google Scholar between July 11–20, 2024 using a keyword/MeSH-adapted query centered on β€œSulforaphane” AND (β€œepigenetic” OR β€œgenetic”) AND (β€œCancer” OR β€œCarcinoma” OR β€œTumor”).
    Inclusion/exclusion criteria were stated as: full-text English original-data articles (2009–July 20, 2024) focusing on SFN and epigenetic effects on cancer, explicitly requiring DNA methylation, histone acetylation, or miRNA expression; reviews/commentaries and non-available full-text were excluded.
    Skeptical note: The paper claims β€œsystematic review” but the provided excerpt does not show a risk-of-bias tool application, quantitative effect-size pooling, or full search strings per database; these omissions limit strength of causal generalization.
    2) PRISMA flow: retained vs excluded (from the paper text)
    (Bar chart uses the counts explicitly reported in the paper excerpt.)
    Interpretation
    The paper reports 35 included studies from an initial 679 identifiers, after removing duplicates and screening down to full-text evaluation and further exclusions. The β€œfinally included” set is then partitioned as 29 studies related to histone modifications + DNA methylation and 6 related to miRNA regulation.
    3) Claimed mechanism chain (epigenetic β†’ gene expression β†’ anticancer phenotypes)
    The review repeatedly asserts the following mechanistic pipeline:
    • HDAC modulation (often decreased HDAC expression/activity) leading to increased histone acetylation and chromatin relaxation.
    • DNMT modulation (downregulation/inhibition of DNMTs, leading to DNA hypomethylation).
    • miRNA promoter methylation changes leading to altered miRNA expression (tumor suppressor miRNAs up; oncomiRs down).
    • Downstream gene expression shifts and phenotypes (apoptosis, cell-cycle arrest, reduced proliferation).
    Importantly, this is a mechanistic narrative built from many heterogeneous primary studies; without quantitative pooling, mechanistic β€œuniversality” remains uncertain.
    4) Mechanistic claims: what strong primary evidence exists in the provided reference set?
    4.1 HDAC inhibition may be metabolism-dependent (parent SFN vs active metabolites)
    A high-signal mechanistic study in the reference set reports that SFN metabolites inhibit HDAC activity and increase histone acetylation and p21 in human cells, while the parent compound shows little to no in vitro HDAC inhibition; it also uses HDAC activity assays and chromatin-related readouts.
    Skeptical implication: the review’s broad β€œSFN is an HDAC inhibitor” phrasing may be context-specific; metabolism and formulation matter.
    4.2 Example epigenetic reprogramming around DNMT/HDAC and Nrf2
    The reference set includes studies reporting that sulforaphane can demethylate or modulate promoter methylation and increase histone acetylation at specific loci in cancer-relevant models, affecting Nrf2-linked transcriptional programs.
    Another provided primary study (in a different model) reports that sulforaphane activates Nrf2 and associates this with reductions in DNMT/HDAC and Nrf2 promoter methylation changes in a JB6 P+ transformation assay context.
    Skeptical implication: promoter-specific effects are plausible, but translating from β€œspecific locus methylation changes” to β€œgeneral epigenetic reprogramming” is a bigger leap.
    4.3 miRNA promoter methylation: a concrete locus-level example
    One locus-level example included in the reference list is miR-9-3 promoter demethylation and reactivation in lung cancer cells following sulforaphane exposure.
    5) Phenotype claims (apoptosis, cell-cycle arrest, and β€œselectivity”)
    The review states that SFN induces apoptosis and/or inhibits proliferation across multiple cancer types and that some studies report sparing normal cells. In your provided reference set, there are also mechanistic and pharmacodynamic papers supporting anti-proliferative behavior in cancer models with epigenetic endpoints.
    Example: An in vivo oral cancer chemoprevention study is cited as showing reduced incidence and size of tongue tumors in a mouse carcinogen model with SFN.
    Important limitation: the excerpted paper section does not provide effect sizes across studies; the β€œselectivity” claim remains vulnerable to publication bias and varying definitions of β€œnormal cells.”
    6) Contradictions / context dependence / known blind spots
    • Mechanism is not always dominant: at least one included reference in your dataset explicitly reports no significant histone PTM changes under specific low-dose combinatorial conditions (SFN+decitabine in B16F10 melanoma) and attributes effects largely to transcriptional/cytokine changes rather than detectable histone remodeling.
    • Epigenetic endpoints are assay-sensitive: methylation measurements vary (bisulfite sequencing vs MSP vs MeDIP), genomic locus selection differs, and β€œglobal methylation” can disagree with locus-specific methylation.
    • Bioavailability and dosing translation: SFN delivery depends on glucoraphanin content, myrosinase conversion, microbiome activity, and formulation. A human study in your reference set shows that broccoli genotype can influence sulforaphane delivery to bloodstream.
    • Endpoint overgeneralization risk: the review moves from mechanistic epigenetic changes to broad claims of prevention/therapy with limited quantitative synthesis and limited human intervention evidence.
    7) Practical β€œwhat you can do with this review” (for a scientist)
    Use the review as a conceptual index into specific epigenetic sub-modules (HDAC classes; DNMTs; miRNA promoter methylation) rather than as a proof of clinical efficacy. Where you need stronger inference, pivot from this review to locus-specific primary papers and to translational studies on bioavailability and target engagement.
    8) Reproducibility & data availability
    The paper states that no datasets were generated or analyzed during the review. That’s typical for reviews, but it makes quantitative re-analysis impossible without access to included full texts and their extracted numeric outcomes (which are not present in the provided excerpt).
    Skeptical note: reproducibility of a systematic review still requires full search strings, study selection reproducibility, and ideally a structured data extraction table.
    Run a Science AI agent (optional)


    Feedback:    

    Updated: March 20, 2026

     BGPT Paper Review


    Study Novelty

    60%

    The mechanistic framing (SFN as an HDAC/DNMT/miRNA-linked epigenetic modulator in cancer) is established in the literature; this work’s contribution is primarily a structured synthesis rather than novel experimental or computational discoveries.


    Scientific Quality

    60%

    Moderate quality as a systematic review: it reports PRISMA adherence and explicit inclusion/exclusion criteria plus a selection flow, but the excerpt does not show quantitative synthesis, risk-of-bias assessment, complete reproducible search strings, or structured extraction of numeric outcomesβ€”limiting causal strength and reproducibility.


    Study Generality

    70%

    It remains broadly relevant to cancer epigenetics and nutraceutical epigenetic targeting, while still being anchored in a specific compound (SFN) and specific epigenetic axes (HDAC/DNMT/miRNA).


    Study Usefulness

    70%

    Useful as a gateway map into epigenetic mechanisms and candidate loci/models; less useful for making clinically actionable claims because it lacks effect-size pooling and strongly translational endpoints in humans.


    Study Reproducibility

    50%

    Reported methods and a PRISMA-style count flow are helpful, but reproducibility would require full database-specific search strings, extraction tables, and risk-of-bias methodology; the paper also reports no datasets were generated for reanalysis.


    Explanatory Depth

    70%

    The paper provides a coherent mechanistic narrative and ties epigenetic regulation to downstream cancer phenotypes, supported by multiple primary studies cited in the reference set, but it does not deeply quantify which mechanisms dominate across contexts.


    🎁 Authors: Collect 123 Free Science Tokens (β‰ˆ $12.3 USD)

    Claim My Author Tokens

    Use for 30 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $12.3 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Parses the paper’s reported selection counts and topic split, then builds charts plus a mechanism taxonomy table mapping each epigenetic axis (HDAC, DNMT, miRNA) to cited mechanistic readouts.



     Hypothesis Graveyard


    β€œSFN is a direct, isoform-independent HDAC inhibitor in all cancer contexts.” Likely weakened because metabolism-dependent HDAC inhibition is reported for SFN metabolites rather than the parent compound in key mechanistic work.


    β€œSFN always produces detectable histone PTM changes under epigenetically meaningful conditions.” Evidence exists for contexts where histone PTMs may not significantly change under certain dosing/combinations, while transcriptional/cytokine shifts still occur.

     Science Art


    Paper Review: Sulforaphane from broccoli, an epigenetic modulator in cancer cells Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Follow the Evidence

    New scientific claims, supporting evidence, and important limitations. Every Friday. No ads.


    My BGPT






     Trending